NCT01843725View on ClinicalTrials.gov

Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Metastatic Colorectal CancersMetastatic Gastric CancersMetastatic Oesophageal CancersMetastatic Pancreatic CancersMetastatic Biliary CancersMetastatic Breast Cancers
Interventions
DRUG

capecitabine

escalation dose of capecitabine continuously

DRUG

aflibercept

Intravenous 6mg/kg every 3 weeks

DRUG

Capecitabine

dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3

Trial Locations (1)

1000

Institut Jules Bordet, Brussels

Sponsors
All Listed Sponsors
lead

Jules Bordet Institute

OTHER